Cosentyx Close To Peak $8bn Sales For Novartis
CEO Vas Narasimhan tells Scrip about the "new energy" driving the decade-old brand which is still the Swiss drugmaker’s biggest seller by some distance.
Scrip - July 21, 2026

Agios Shelves Tebapivat In Sickle Cell, Weeks After MDS Exit
Agios’s shares took a hit after it scrapped tebapivat in sickle cell disease, the drug’s second failure in under two months, with mitapivat now its only shot in sickle cell.
Scrip - July 21, 2026

Stock Watch: Johnson & Johnson Gets No Credit For Weathering The Stelara Cliff
Johnson & Johnson delivered 6.6% second-quarter sales growth and raised full-year guidance, yet its stock fell nearly 3% on the day. Concerns over medical devices, talc litigation and future loss of blockbuster drug exclusivity seemed to be overweight in investors’ assessment of the company.
Scrip - July 21, 2026

J&J On How Imaavy Can Compete In The FcRn Field
J&J's immunology medical affairs leader Mark Graham talks to Scrip how the company is sequencing indications for the FcRn inhibitor Imaavy.
Scrip - July 21, 2026

Lupin Spins Off, Licenses Two Oncology Assets In Renewed Funding Attempt
Lupin has spun off a PRMT5 inhibitor and an SOS1 asset, licensing them to Kaveri Therapeutics in return for a 82.2% stake. Initially supported by seed funding from Lupin, the US-based entity will seek to raise funds in a renewed attempt at taking oncology assets to global clinical trials
Scrip - July 21, 2026

Clinical Trial Complexity Is Reshaping Evidence Collection
As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.
Scrip - July 21, 2026

Chinese Anti-Infectives Specialist Trinomab Grosses $148m In Shanghai IPO
Trinomab becomes the first biotech to wrap up an IPO on the Shanghai STAR Market this year, raking in new funds to support its pipeline of novel anti-infective antibodies.
Scrip - July 21, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: J&J ups guidance; Gilead’s acquisition strategies; Bayer breakup rumors; Biogen’s Alzheimer’s results; and an interview with Lilly’s blood test pioneer.
Scrip - July 21, 2026

FDA Tightens Stance On Terumo’s RelayPro: Return The Devices, Don’t Use Them
The FDA has told clinicians to return the recalled RelayPro thoracic stent-grafts to the maker rather than keep using them cautiously — a tightening from earlier notices.
Medtech Insight - July 21, 2026

CorTec’s BCI Shows Early Promise In Stroke Rehab With 8 to 12 Point FMA-UE Gains
CorTec’s implantable BCI system has shown early safety and functional gains in three stroke patients, with Fugl-Meyer (FMA-UE) upper extremity improving by 8-12 points. Rivals Neurolutions, Mobia Medical and Enspire leverage EEG, VNS and DBS technologies respectively also use FMA-UE as benchmark.
Medtech Insight - July 21, 2026

IFF Trims Business Focus While SuanNutra Adds Scale In Supplement Ingredients Portfolio Deal
Deal expected to close during 2026 includes IFF’s portfolio of botanical extracts, vitamins and minerals and food enhancement activities, including its natural colors and antioxidants and some flavor activities in Peru. Financial terms weren’t disclosed.
HBW Insight - July 20, 2026

‘World’s Best-Smelling Sunscreen’ Claim Puffery Until Paired With Reviews – NAD
The National Advertising Division reviewed a challenge brought by Nivea marketer Beiersdorf against Vacation for ‘World’s Best-Smelling Sunscreen’ claim.
HBW Insight - July 20, 2026

EU Regulators Flag Probiotics And Ginseng Supplements As Possible ‘Emerging Risks’
Six food supplement ingredients, including ginseng and the probiotic bifidobacterium, have been flagged as possible emerging risks by EU regulators, raising the prospect of future sales restrictions across the bloc.
HBW Insight - July 20, 2026

No-Regrets Move: PwC Makes The Case For Building Consumer Health Innovation Around Wellness Goals
Consumers are managing their health continuously and across more product categories than ever. PwC's Anthony Bruce says this presents an opportunity for consumer health firms to orientate innovation around the goals, such as sleep, immunity and healthy aging, that consumers are already focused on.
HBW Insight - July 20, 2026

Supplement Industry Plants Longtime Use Flag As US Looks At Expanding Peptide Bulk Drugs List
FDA Pharmacy Compounding Advisory Committee on July 23-24 will review numerous peptides for addition to its bulk list for compounding by state-licensed physicians and pharmacists under FD&C Act Section 503A.
HBW Insight - July 20, 2026

Henlius Advances Darzalex And Opdivo Biosimilar Trials
Henlius has dosed the first patients across four biosimilar programs this summer, advancing daratumumab, nivolumab, cetuximab, and ipilimumab candidates in the US and China.
Generics Bulletin - July 21, 2026

Inspection Findings Highlight Hurdles Facing Alvotech’s Launch Plans
An FDA inspection has found continuing quality-system deficiencies at Alvotech’s Reykjavik plant, where manufacturing issues have already delayed several US biosimilar applications.
Generics Bulletin - July 21, 2026

Canadian Generics Face Tougher Path Around Dosing Regimen Patents
Canada’s Supreme Court has upheld Janssen’s Invega Sustenna dosing patent, blocking Pharmascience’s generic and setting a new test focusing on whether claims constrain physicians’ clinical judgment.
Generics Bulletin - July 21, 2026

Dr Reddy’s Bottleneck Stalls Aspen’s Canadian Semaglutide Ambitions
Aspen has won Canadian approval for generic injectable semaglutide, but API supply problems at Dr Reddy’s have delayed commercialization and could weaken its early-mover advantage.
Generics Bulletin - July 21, 2026

Podcast: How ElevateBio Is Betting On Every Gene Editing Modality At Once
ElevateBio's CSO Amy Pooler on why no single gene editing modality will dominate, and how AI-designed enzymes and smarter delivery could finally unlock large gene therapies.
In Vivo - July 21, 2026

The Biggest Launches In Pharma History Are Increasingly Forecasts, Not Records
Evaluate data on the biggest drug launches ever shows actual sales topping the table at year three – led by COVID-19 vaccines – before forecasts take over at years five and 10, almost entirely incretin assets. Counted as one franchise, Lilly's tirzepatide approaches $72bn by year 10.
In Vivo - July 21, 2026